DOCSLIB.ORG

Proteolysis in the Postgenomic Era August 27-31, 2006 San Diego, California, USA San Diego Convention Center

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proteolysis in the Postgenomic Era August 27-31, 2006 San Diego, California, USA San Diego Convention Center Abstracts of the 18th International Congress on Fibrinolysis and Proteolysis Proteolysis in the Postgenomic Era August 27-31, 2006 San Diego, California, USA San Diego Convention Center CONTENTS Abstract ID# Index……………………………………2 Abstract Table of Contents Plenary Sessions ………………………………3 (in order of presentation) State of the Art ………………………………3 (in order of presentation) Oral and Poster Abstracts ……………………7 (in order of category) Author Index ………………………………………245 Publication of Abstracts Abstracts will be posted on the Blackwell Synergy site and will be available to all JTH subscribers. http://www.blackwell-synergy.com/loi/jth The abstracts have also been published on a CD rom and will be cited as “Abstracts CD-Rom, Supplement I to Volume 4, 2006, Journal of the International Society on Thrombosis and Haemostasis.” The abstract CD is included with this syllabus and will be distributed with the October issue of the JTH. 1 ISFP 2006 San Diego - 18th International Congress on Fibrinolysis and Proteolysis Table of Contents Abstract ID# Index ID# Page# ID# Page# ID# Page# ID# Page# 1 …………………109 113 …………………30 210 ……………… 116 291 ………………104 4 …………………125 117 …………………70 212 ………………168 292 ………………175 6 …………………… 54 118 …………………86 214 ………………141 294 …………………78 8 …………………… 27 119 ………………… 71 217 ……………… 193 295 …………………93 9 ……………………96 120 ………………164 218 …………………60 296 …………………95 11 …………………179 122 ………………218 220 …………………74 298 ………………183 12………………… 226 126 ……………… 219 221 …………………47 299 ………………124 15 …………………180 129 ………………135 222 ………………123 300 …………………49 16 ………………… 25 130 ………………136 224 ………………229 303 ………………194 21 …………………190 131 ………………197 225 ………………169 305 …………………79 22 …………………153 133 ………………147 228 …………………94 307 …………………65 24 …………………148 134 …………………87 229 ………………170 310………………… 80 29 ………………… 58 135 …………………88 231 ………………103 311 ………………176 31 …………………158 136 ………………111 233 ………………171 312 …………………81 34 …………………159 138 ………………198 235 …………………53 314 ……………… 235 35 …………………35 141 ………………202 237 ………………186 316 …………………82 37 …………………154 142 ………………137 238 …………………50 317 …………………37 38 …………………97 145 ………………118 240………………… 91 318 …………………48 41 …………………112 147 ………………119 241 ………………130 319 ………………157 47 …………………155 151 ………………156 242 ………………210 320 …………………24 48 …………………98 152 …………………26 243 ………………211 321………………… 36 49 …………………149 154 ………………165 244 ………………212 323 …………………69 53 …………………195 155 ………………101 246 ………………121 326 ………………214 54 …………………131 156 ………………203 247 …………………75 327 ……………… 215 55 …………………160 157 …………………89 248 ………………142 328………………… 62 57 ………………… 99 165 ………………138 250 ………………172 330 …………………38 58 …………………67 166 ………………102 251………………… 51 331 ………………177 61 …………………113 167 ………………105 252 ………………108 334 ………………117 64 …………………132 168 ………………106 254 …………………56 335 …………………28 65 …………………161 171 ………………166 255 …………………40 337 …………………61 66………………… 216 174 ………………122 256 ……………… 222 338 ………………236 68 …………………196 175 ………………107 257 ………………230 340 ………………187 69 …………………126 176 ……………… 150 258 ………………225 341 ………………188 70 ………………… 114 178 ………………228 259 ………………213 342 …………………63 71………………… 133 179 ……………… 220 260 ………………242 343 ……………… 200 75………………… 134 184 ……………… 204 261 ………………231 348 ……………… 237 81 …………………184 186 ………………151 262 ………………232 350 …………………23 86………………… 227 187 ……………… 205 263 …………………92 351………………… 34 87………………… 241 188 ……………… 206 264 …………………45 352 …………………64 89 …………………100 189 ………………207 265 …………………31 356 …………………41 90 …………………84 190 ………………167 267 …………………42 357 …………………52 91 ………………… 85 191 …………………72 269 ………………233 358 …………………55 95 …………………178 194 ………………181 274 ………………234 359 ………………238 96 …………………185 195 …………………73 275 ………………240 360 ………………144 97 …………………115 196 ………………152 276 …………………39 361 ………………239 98 ………………… 68 197 …………………44 277 ………………143 363 ………………145 101 ……………… 217 199 ………………208 279 ………………173 365 ………………146 103 ……………… 223 200 ………………139 280 …………………76 366 …………………59 105 ……………… 201 201 …………………90 281 …………………77 368 ………………189 106 ………………162 203 ………………192 282 ………………174 369 …………………57 107 ………………163 204 ………………221 284 ………………199 370………………… 29 108 ………………127 205 …………………33 285 ………………110 371………………… 32 109 ………………224 206 ………………209 287 ………………182 372………………… 83 110 ……………… 128 208 ………………140 288 ……………… 243 373 …………………46 111 ………………129 209 ………………120 289 …………………43 2 ISFP 2006 San Diego - 18th International Congress on Fibrinolysis and Proteolysis Table of Contents TABLE OF CONTENTS Plenary Sessions (listed in order of presentation) 350 Characterization of an Extracellular Proteolytic Signaling Pathway in Cancer……………………………………………23 C. Craik 320 The Intriguing side of the Hemostatic Balance ………………………………………………………………………………………24 J. Degen 16 Structural aspects of urokinase-type plasminogen activator receptor (uPAR) function ………………………………25 M. Ploug 152 Proteolytic pathways in cell death ………………………………………………………………………………………………………26 G. Salvesen State of the Art (listed in order of presentation) Proteomics 8 Mass Spectrometry Driven Biological Discovery ……………………………………………………………………………………27 J. Yates 335 Activity-based proteomics of proteases in human disease ………………………………………………………………………28 B. Cravat 370 CLIP-TAILS and CLIP-STEP: New Degradomic Techniques for the Discovery of Natural Substrates and Proteases in Complex Cell Proteomes …………………………………………………………………29 C. Overall Cancer 113 uPA and PAI-1: Clinically Validated Biomarkers in Breast Cancer ……………………………………………………………30 M. Duffy 265 Tumor Microenvironment and Proteolysis ……………………………………………………………………………………………31 B. Sloane 371 Proangiogenic Function of Plasminogen Activator Inhibitor-1 (PAI-1) in Angiogenesis: PAI-1 Protects Endothelial Cells from FasL-induced Apoptosis ………………………………………………………………32 Y. DeClerck, K. Bajou, W. Laug, H. Peng, P. DeClerck, A. Noel, J. Foidart 3 ISFP 2006 San Diego - 18th International Congress on Fibrinolysis and Proteolysis Table of Contents State of the Art PAI-1/Joe Shore Symposium 205 MONOCLONAL ANTIBODIES IN THE RATIONAL DESIGN OF PAI-1 MODULATING COMPOUNDS ……………………33 P. DeClerck, A. Gils 351 PAI-1 and Vascular Pathology: Insights from Genetically Modified Mice …………………………………………………34 D. Vaughan 35 Role of the fibrinolytic system in the development of obesity and the metabolic syndrome ………………………35 M. Alessi, I. Juhan-Vague Stroke 321 Matrix Protease Responses of the Neurovascular Unit During Ischemic Stroke …………………………………………36 G. del Zoppo 317 Matrix metalloproteinases in brain injury, hemorrhage and remodeling after stroke …………………………………37 E. Lo 330 Neuroprotective mechanisms of activated protein C ………………………………………………………………………………38 B. Zlokovic Vascular Biology/Angiogenesis 276 Angiostatin4.5: From the Bench To The Bedside ……………………………………………………………………………………39 G. Soff, H. Wang, D. Cundiff, K. Ridge, T. Kuzel 255 Effects of PAI-1 on Endothelial Cell Signaling and Function ……………………………………………………………………40 V. Ploplis 356 Distinct roles for cysteine cathepsins in multistage tumorigenesis …………………………………………………………41 V. Gocheva, W. Zeng, D. Ke, D. Klimstra, T. Reinheckel, C. Peters, D. Hanahan, J. Joyce Functional Imaging 267 Thrombus Formation In Vivo ………………………………………………………………………………………………………………42 B.C. Furie, B. Furie 289 Dynamic imaging of protease location and function in ECM remodeling ……………………………………………………43 P. Friedl 197 In vivo Imaging of protease activity using fluorescent activity based probes……………………………………………44 M. Bogyo, G. Blum, G. von Degenfeld, H. Blau 4 ISFP 2006 San Diego - 18th International Congress on Fibrinolysis and Proteolysis Table of Contents State of the Art Matrix Metalloproteinases 264 Matrix Regulation of Ovarian Cancer Metastasis ……………………………………………………………………………………45 M. Stack, J. Symowicz, M. Barbolina, L. Hudson 373 MMP-9-dependent regulation of angiogenesis and invasion in GBM …………………………………………………………46 R. Du, C. Petritsch, H. Song, Z. Werb, G. Bergers 221 Proteolytic Remodeling of the 3-Dimensional Extracellular Matrix …………………………………………………………47 S. Weiss Receptors 318 A Tale of Two Plasminogen Receptors …………………………………………………………………………………………………48 E. Plow, R. Das, T. Burke, E. Pluskota 300 Urokinase Receptor-dependent Cell Signaling ………………………………………………………………………………………49 S. Gonias, M. Jo, V. Montel, R. Lester 238 Protease Signaling in Angiogenesis and Cancer ……………………………………………………………………………………50 W. Ruf New Thrombolytic Therapies 251 Engineered Human Proteases (Alterases) as a Broad New Therapeutic Modality ………………………………………51 E. Madison, S. Waugh-Ruggles, K. Tachias, J. Nguyen 357 Plasmin: A Direct Thrombolytic Agent …………………………………………………………………………………………………52 V. Marder 235 Microplasmin: A novel, direct-acting thrombolytic for treatment of acute vascular occlusions ……………………53 S. Pakola, D. Collen Protein C/Plasminogen and Infection 6 Thrombosis and thrombolysis in host defense from microbial pathogens …………………………………………………54 D. Ginsburg 358 Protein C……………………………………………………………………………………………………………………………………………55 J. Griffin 254 Protein C at the Crossroads of Coagulation and Inflammation…………………………………………………………………56 F. Castellino 5 ISFP 2006 San Diego - 18th International Congress on Fibrinolysis and Proteolysis Table of Contents State of the Art Membrane Proteases 369 Membrane serine proteases and cell morphogenesis………………………………………………………………………………57 T. Antalis 29 The pro-uPA activator matriptase: key regulator of epidermal development and epithelial carcinogenesis ……………………………………………………………………………………………………………………58 T. Bugge, K. List, R. Szabo, A. Molinolo 366 MT1-MMP Controls Tumor-Induced Angiogenesis through Release of Semaphorin 4D ………………………………59 J. Basile, K. Holmbeck, T. Bugge, J. Gutkind Neurosciences 218 Tissue plasminogen activator and the interplay between neurons and microglia ………………………………………60 S. Tsirka, I. Gravanis, J. Sheehan, C. Zhou, S. Parathath 337 Tissue
Load more

Recommended publications
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Characterization of a Novel Metalloproteinase in Duvernoy's Gland of Rhabdophis Tigrinus Tigrinus
    The Journal of Toxicological Sciences, 157 Vol.31, No.2, 157-168, 2006 CHARACTERIZATION OF A NOVEL METALLOPROTEINASE IN DUVERNOY’S GLAND OF RHABDOPHIS TIGRINUS TIGRINUS Koji KOMORI1, Motomi KONISHI1, Yuji MARUTA1, Michihisa TORIBA2, Atsushi SAKAI2, Akira MATSUDA3, Takamitsu HORI3, Mitsuko NAKATANI4, Naoto MINAMINO4 and Toshifumi AKIZAWA1 1Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotogecho, Hirakata, Osaka 573-0101, Japan 2The Japan Snake Institute, 3318 Yabuzuka Ota, Gunma 379-2301, Japan 3Department of Biochemistry, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan 4Department of Pharmacology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan (Received January 31, 2006; Accepted February 20, 2006) ABSTRACT — During the characterization of hemorrhagic factor in venom of Rhabdophis tigrinus tigri- nus, so-called Yamakagashi in Japan, one of the Colubridae family, a novel metalloproteinase with molec- ular weight of 38 kDa in the Duvernoy’s gland of Yamakagashi was identified by gelatin zymography and by monitoring its proteolytic activity using a fluorescence peptide substrate, MOCAc-PLGLA2pr(Dnp)AR-NH2, which was developed for measuring the well-known matrix metalloproteinase (MMP) activity. After purification by gel filtration HPLC and/or column switch HPLC system consisting of an affin- ity column, which was immobilized with a synthetic BS-10 peptide (MQKPRCGVPD) originating from propeptide domain of MMP-7 and a reversed-phase column, the N-terminal amino acid sequence of the 38 kDa metalloproteinase was identified as FNTFPGDLK which shared a high homology to Xenopus MMP-9. The 38 kDa metalloproteinase required Zn2+ and Ca2+ ions for its proteolytic activity.
    [Show full text]
  • Final Program N
    XXII Congress The International Society on Thrombosis and Haemostasis B July 11-16 2009 O 55th Annual Meeting S of the Scientific and Standardization Committee of the ISTH T O Final Program N Boston - July 11-16 2009 XXII Congress of the International Society on Thrombosis and Haemostasis 2009 Table ISTH of Contents Venue and Contacts 2 Wednesday 209 Welcome Messages 3 – Plenary Lectures 210 Committees 7 – State of the Art Lectures 210 Congress Awards and Grants 15 – Abstract Symposia Lectures 212 Other Meetings 19 – Oral Communications 219 – Posters 239 ISTH Information 20 Program Overview 21 Thursday 305 SSC Meetings and – Plenary Lectures 306 Educational Sessions 43 – State of the Art Lectures 306 – Abstract Symposia Lectures 309 Scientific Program 89 – Oral Communications 316 Monday 90 – Posters 331 – Plenary Lectures 90 Nursing Program 383 – State of the Art Lectures 90 Special Symposia 389 – Abstract Symposia Lectures 92 Satellite Symposia 401 – Oral Communications 100 – Posters 118 Technical Symposia Sessions 411 Exhibition and Sponsors 415 Tuesday 185 – Plenary Lectures 186 Exhibitor and Sponsor Profiles 423 – State of the Art Lectures 186 Congress Information 445 – Abstract Symposia Lectures 188 Map of BCEC 446 – Oral Communications 196 Hotel and Transportation Information 447 ISTH 2009 Congress Information 452 Boston Information 458 Social Events 463 Excursions 465 Authors’ Index 477 1 Venue & Contacts Venue Boston Convention & Exhibition Center 415 Summer Street - Boston, Massachusetts 02210 - USA Phone: +1 617 954 2800 - Fax: +1 617 954 3326 The BCEC is only about 10 minutes by taxi from Boston Logan International Airport. The 2009 Exhibition is located in Hall A and B of the Exhibit Level of the BCEC, along with posters and catering.
    [Show full text]
  • Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 203639, 19 pages http://dx.doi.org/10.1155/2014/203639 Review Article Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy Leonardo A. Calderon,1 Juliana C. Sobrinho,1 Kayena D. Zaqueo,1 Andrea A. de Moura,1 Amy N. Grabner,1 Maurício V. Mazzi,2 Silvana Marcussi,3 Auro Nomizo,4 CarlaF.C.Fernandes,1 Juliana P. Zuliani,1 Bruna M. A. Carvalho,5 Saulo L. da Silva,5 Rodrigo G. Stábeli,1 and Andreimar M. Soares1 1 Centro de Estudos de Biomoleculas´ Aplicadas aSa` ude,´ CEBio, Fundac¸ao˜ Oswaldo Cruz, Fiocruz Rondoniaˆ e Departamento de Medicina, Universidade Federal de Rondonia,ˆ UNIR, Porto Velho, RO, Brazil 2 Fundac¸ao˜ Herm´ınio Ometto, UNIARARAS, Nucleo´ de Cienciasˆ da Saude-NUCISA,´ 13607-339 Araras, SP, Brazil 3 Departamento de Qu´ımica, Universidade Federal de Lavras, UFLA, 37200-000 Lavras, MG, Brazil 4 Departamento de Analises´ Cl´ınicas, Toxicologicas´ e Bromatologicas,´ Faculdade de Cienciasˆ Farmaceuticasˆ de Ribeirao˜ Preto, Universidade de Sao˜ Paulo, USP, Ribeirao˜ Preto, SP, Brazil 5 Departamento de Qu´ımica, Biotecnologia e Engenharia de Bioprocessos, Universidade Federal de Sao˜ Joao˜ del Rei, UFSJ, Campus Alto paraopeba, Ouro Branco, MG, Brazil Correspondence should be addressed to Andreimar M. Soares; [email protected] Received 20 September 2013; Revised 7 December 2013; Accepted 8 December 2013; Published 13 February 2014 Academic Editor: Fernando Albericio Copyright © 2014 Leonardo A. Calderon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • Structural, Functional and Therapeutic Aspects of Snake Venom Metal- Loproteinases
    Send Orders for Reprints to [email protected] 28 Mini-Reviews in Organic Chemistry, 2014, 11, 28-44 Structural, Functional and Therapeutic Aspects of Snake Venom Metal- loproteinases P. Chellapandi* Department of Bioinformatics, School of Life Sciences, Bharathidasan University, Tiruchirappalli-620024, Tamil Nadu, India Abstract: Snake venoms are rich sources of metalloproteinases that are of biological interest due to their diverse molecu- lar diversity and selective therapeutic applications. Snake venoms metalloproteinases (SVMPs) belong to the MEROPS peptidase family M12B or reprolysin subfamily, which are consisted of four major domains include a reprolysin catalytic domain, a disintegrin domain, a reprolysin family propeptide domain and a cysteine-rich domain. The appropriate struc- tural and massive sequences information have been available for SVMPs family of enzymes in the Protein Data Bank and National Center for Biotechnology Information, respectively. Functional essentiality of every domain and a crucial contri- bution of binding geometry, primary specificity site, and structural motifs have been studied in details, pointing the way for designing potential anti-coagulation, antitumor, anti-complementary and anti-inflammatory drugs or peptides. These enzymes have been reported to degrade fibrinogen, fibrin and collagens, and to prevent progression of clot formation. An- giotensin-converting enzyme activity, antibacterial properties, haemorrhagic activity and platelet aggregation response of SVMPs have been studied earlier. Structural information of these enzymes together with recombinant DNA technology would strongly promote the construction of many recombinant therapeutic peptides, particularly fibrinogenases and vac- cines. We have comprehensively reviewed the structure-function-evolution relationships of SVMPs family proteins and their advances in the promising target models for structure-based inhibitors and peptides design.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • Full Technical Program 1 1 / 3 0 / 2 112/03/11 12:48 AM Instructions Index of Organizing Groups Program (Listing of Papers) Technical
    Full Technical Program Full Technical • Instructions • Index of Organizing Groups • Technical Program (Listing of Papers) AACS-ANAHEIM-11-0201-Onsite.inddCS-ANAHEIM-11-0201-Onsite.indd 5555 112/03/112/03/11 112:482:48 AAMM How to Read the Technical Program 1) Search for the Division (listed in alphabetical order). 2) Locate the day (Sunday, Monday, etc.). 3) Locate the time of day (morning, afternoon, evening). 4) Locate the session name and oral presentation start time or poster session duration. 5) Locate the venue and room for each session. FULL TECHNICAL PROGRAM wenty-nine of the society's techni- In addition to this technical program- are expected to attend the ever-popular cal divisions and seven commit- ming, there is one cross divisional Sci-Mix Interdivisional Poster Session Ttees are hosting original technical theme of Chemistry of Natural Resourc- & Mixer on Monday, March 28 from 8 programming during the meeting. More es that is contributed by numerous to 10 PM at the Anaheim Convention than 9,000 papers have been ac- ACS divisions. Each organizing group's Center. Approximately 600 noteworthy cepted for this meeting. ACS President programming is detailed on the poster presentations, networking with Nancy B. Jackson is cosponsoring following pages. More than 2,000 colleagues, and light refreshments two symposia during the meeting. chemical professionals and students make up this enjoyable event. Organizing Group Acronym Page Organizing Group Acronym Page Presidential & Cross-Division Programming Inorganic Chemistry INOR TECH-134
    [Show full text]
  • Crystal Structure Analysis of a Snake Venom Metalloproteinase In
    Crystal structure analysis of a snake venom metalloproteinase in complex with an inhibitor as basis for considerations on the proteolytic activity and the hemorrhagic mode of action INAUGURALDISSERTATION zur Erlangung der Doktorwürde der Fakultät für Chemie, Pharmazie und Geowissenschaften Albert-Ludwigs Universität Freiburg im Breisgau vorgelegt von Torsten Jens Lingott aus Bayreuth Freiburg im Breisgau November 2010 Tag der Bekanntgabe des Prüfungsergebnisses: 16.12.2010 Dekan: Prof. Dr. H. Hillebrecht Referentin: Prof. Dr. I. Merfort Korreferent: Prof. Dr. J. M. Gutiérrez Drittprüfer: Prof. Dr. A. Bechthold Parts of this thesis have been or are prepared to be published in the following articles: Lingott, T., Schleberger, C., Gutiérrez, J. M., and Merfort, I. (2009). High-resolution crystal structure of the snake venom metalloproteinase BaP1 complexed with a peptidomimetic: insight into inhibitor binding. Biochemistry 48 , 6166-6174. Wallnoefer, H. G., Lingott, T., Gutiérrez, J. M., Merfort, I., and Liedl, K. R. (2010). Backbone flexibility controls the activity and specificity of a protein-protein interface: Specificity in snake venom metalloproteases. J Am Chem Soc 132 , 10330-10337. Lingott, T. and Merfort, I. (xxxx). The catalytic domain of snake venom metalloproteinases - Sequential and structural considerations. in preparation. Wallnoefer, H. G.*, Lingott, T.*, Escalante, T., Ferreira, R. N., Nagem, R. A. P., Gutiérrez, J. M., Merfort, I., and Liedl, K. R. (xxxx). The hemorrhagic activity of P-I snake venom metalloproteinases
    [Show full text]
  • Neural Computation for Rehabilitation Animal Toxins and Their Advantages in Biotechnology and Pharmacology
    BioMed Research International Animal Toxins and Their Advantages in Biotechnology and Pharmacology Guest Editors: S. L. Da Silva, E. G. Rowan, F. Albericio, R. G. Stábeli, NeuralL. A. Calderon, Computation and A. M. Soares for Rehabilitation Animal Toxins and Their Advantages in Biotechnology and Pharmacology BioMed Research International Animal Toxins and Their Advantages in Biotechnology and Pharmacology Guest Editors: S. L. Da Silva, E. G. Rowan, F. Albericio, R. G. Stabeli,´ L. A. Calderon, and A. M. Soares Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “BioMed Research International.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Contents Animal Toxins and Their Advantages in Biotechnology and Pharmacology,S.L.DaSilva,E.G.Rowan, F. Albericio, R. G. Stabeli,´ L. A. Calderon, and A. M. Soares Volume 2014, Article ID 951561, 2 pages Alkylation of Histidine Residues of Bothrops jararacussu Venom Proteins and Isolated Phospholipases A2: A Biotechnological Tool to Improve the Production of Antibodies,C.L.S.Guimaraes,˜ S. H. Andriao-Escarso,L.S.Moreira-Dill,B.M.A.Carvalho,D.P.Marchi-Salvador,N.A.Santos-Filho,˜ C. A. H. Fernandes, M. R. M. Fontes, J. R. Giglio, B. Barraviera, J. P. Zuliani, C. F. C. Fernandes, L. A. Calderon,´ R. G. Stabeli,´ F. Albericio, S. L. da Silva, and A. M. Soares Volume 2014, Article ID 981923, 12 pages Biochemical and Functional Characterization of Parawixia bistriata Spider Venom with Potential Proteolytic and Larvicidal Activities, Gizeli S.
    [Show full text]
  • Expert Review Stability of Protein Pharmaceuticals: an Update
    Pharmaceutical Research, Vol. 27, No. 4, April 2010 (# 2010) DOI: 10.1007/s11095-009-0045-6 Expert Review Stability of Protein Pharmaceuticals: An Update Mark Cornell Manning,1,4 Danny K. Chou,2 Brian M. Murphy,1 Robert W. Payne,1 and Derrick S. Katayama3 Received October 6, 2009; accepted December 27, 2009; published online February 9, 2010 Abstract. In 1989, Manning, Patel, and Borchardt wrote a review of protein stability (Manning et al., Pharm. Res. 6:903–918, 1989), which has been widely referenced ever since. At the time, recombinant protein therapy was still in its infancy. This review summarizes the advances that have been made since then regarding protein stabilization and formulation. In addition to a discussion of the current understanding of chemical and physical instability, sections are included on stabilization in aqueous solution and the dried state, the use of chemical modification and mutagenesis to improve stability, and the interrelationship between chemical and physical instability. KEY WORDS: formulation; protein stability; protein stabilization. INTRODUCTION the physical state of the protein does change. This includes denaturation, aggregation, precipitation, and adsorption In 1989, Manning, Patel and Borchardt wrote a review (Table I). The term precipitation is used here to denote summarizing what was known at the time about the stability insolubility rather than insoluble aggregate formation. and stabilization of protein pharmaceuticals (1), an article Our knowledge of all protein degradation pathways is that has been referenced almost 500 times. In the late 1980s, markedly greater than it was 20 years ago. Therefore, the there were only three recombinant protein products on the emphasis of this review is on the progress that has been made US market: Orthoclone (OKT-3), human insulin, and tissue since 1989.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]